RxDoctor Payments Data

Lawrence Greenberg, DO

Nephrology · Lake Orion, MINPI 1568459196

Payments from drug & device makers

$1,125in general payments, 2019–2025

Across 48 payments — averaging $23.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$258
  • Vifor Pharma, Inc.$200
  • Johnson & Johnson$150
  • Bayer$80
  • Axsome Therapeutics, Inc.$61
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$60
  • plus $316 from 15 others

What the payments were for

  • Consulting fees$605%
  • Speaking & faculty fees$20018%
  • Food & beverage$82874%
  • Education$373%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,125 in reported general payments places this provider in the 55th percentile of 325 nephrology providers in Michigan.

See all nephrology providers in Michigan

Medicare billing

Part B allowed, 2024
$53,048
Medicare patients
46
Services billed
393

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4612$97,158
OpzeluraRuxolitinib Phosphate12$24,540
VelphoroSucroferric Oxyhydroxide11$23,570
FarxigaDapagliflozin Propanediol29$20,945
OzempicSemaglutide18$17,399
RybelsusSemaglutide13$12,678
EliquisApixaban15$9,877
XareltoRivaroxaban12$6,544
Sevelamer Carbonate15$1,943
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl15$916
Midodrine Hcl13$703
Oxycodone Hcl29$570
Colchicine11$429
Atorvastatin Calcium38$407
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen27$348

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$20$30,07731 claims
PfizerEliquis$21$9,87715 claims
Johnson & JohnsonXarelto$150$6,54412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 325 nephrology providers in Michigan.

Other nephrology in Lake Orion

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →